Fuji Pharma Co., Ltd. (4554.T)
JPY 1317.0
(1.7%)
JPY 1317.0
(1.7%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 6.88 Billion JPY | 6.61% |
| 2022 | 6.52 Billion JPY | 26.35% |
| 2021 | 5.45 Billion JPY | 6.52% |
| 2020 | 5.19 Billion JPY | -18.4% |
| 2019 | 6.3 Billion JPY | -7.97% |
| 2018 | 6.64 Billion JPY | 1.15% |
| 2017 | 6.33 Billion JPY | 28.39% |
| 2016 | 5.49 Billion JPY | -0.17% |
| 2015 | 5.33 Billion JPY | 6.41% |
| 2014 | 4.82 Billion JPY | 1.2% |
| 2013 | 4.67 Billion JPY | 3.85% |
| 2012 | 3.54 Billion JPY | -12.75% |
| 2011 | 4.52 Billion JPY | 7.44% |
| 2010 | 4.97 Billion JPY | 21.65% |
| 2009 | 3.42 Billion JPY | 16.31% |
| 2008 | 3.51 Billion JPY | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | 2.45 Billion JPY | -53.3% |
| 2024 Q1 | 694 Million JPY | 91.09% |
| 2024 Q3 | 1.52 Billion JPY | -31.0% |
| 2023 Q3 | 622 Million JPY | -11.27% |
| 2023 Q4 | 1.61 Billion JPY | 160.29% |
| 2023 FY | - JPY | 6.61% |
| 2023 Q1 | 1.32 Billion JPY | 547.06% |
| 2023 Q2 | 701 Million JPY | -46.89% |
| 2022 Q2 | 1.3 Billion JPY | -18.58% |
| 2022 Q1 | 1.6 Billion JPY | 586.06% |
| 2022 FY | - JPY | 26.35% |
| 2022 Q4 | 204 Million JPY | -79.06% |
| 2022 Q3 | 974 Million JPY | -25.42% |
| 2021 Q2 | 1.01 Billion JPY | -41.7% |
| 2021 FY | - JPY | 6.52% |
| 2021 Q1 | 1.74 Billion JPY | 106.77% |
| 2021 Q3 | 876 Million JPY | -13.69% |
| 2021 Q4 | -330 Million JPY | -137.67% |
| 2020 Q1 | 1.09 Billion JPY | 135.7% |
| 2020 FY | - JPY | -18.4% |
| 2020 Q2 | 532 Million JPY | -51.46% |
| 2020 Q3 | 550 Million JPY | 3.38% |
| 2020 Q4 | 842 Million JPY | 53.09% |
| 2019 Q4 | 465 Million JPY | -62.04% |
| 2019 FY | - JPY | -7.97% |
| 2019 Q1 | 1.51 Billion JPY | 63.71% |
| 2019 Q2 | 892 Million JPY | -40.97% |
| 2019 Q3 | 1.22 Billion JPY | 37.33% |
| 2018 Q2 | 545 Million JPY | -70.3% |
| 2018 Q1 | 1.83 Billion JPY | 125.43% |
| 2018 Q3 | 1.2 Billion JPY | 121.47% |
| 2018 Q4 | 923 Million JPY | -23.53% |
| 2018 FY | - JPY | 1.15% |
| 2017 FY | - JPY | 28.39% |
| 2017 Q3 | 1.29 Billion JPY | 27.56% |
| 2017 Q2 | 1.01 Billion JPY | -33.81% |
| 2017 Q1 | 1.53 Billion JPY | 119.29% |
| 2017 Q4 | 814 Million JPY | -37.19% |
| 2016 Q4 | 700 Million JPY | -16.47% |
| 2016 FY | - JPY | -0.17% |
| 2016 Q1 | 856 Million JPY | -4.25% |
| 2016 Q2 | 891 Million JPY | 4.09% |
| 2016 Q3 | 838 Million JPY | -5.95% |
| 2015 Q3 | 747 Million JPY | 16.9% |
| 2015 FY | - JPY | 6.41% |
| 2015 Q1 | 856 Million JPY | -8.25% |
| 2015 Q2 | 639 Million JPY | -25.35% |
| 2015 Q4 | 894 Million JPY | 19.68% |
| 2014 FY | - JPY | 1.2% |
| 2014 Q4 | 933 Million JPY | 40.3% |
| 2014 Q3 | 665 Million JPY | -12.96% |
| 2014 Q2 | 764 Million JPY | -16.87% |
| 2014 Q1 | 919 Million JPY | -12.89% |
| 2013 Q4 | 1.05 Billion JPY | 71.54% |
| 2013 Q3 | 615 Million JPY | -21.25% |
| 2013 FY | - JPY | 3.85% |
| 2013 Q2 | 781 Million JPY | -19.98% |
| 2013 Q1 | 976 Million JPY | -52.03% |
| 2012 Q1 | 766.07 Million JPY | -62.38% |
| 2012 Q4 | 2.03 Billion JPY | 94.53% |
| 2012 Q3 | 1.04 Billion JPY | 28.11% |
| 2012 FY | - JPY | -12.75% |
| 2012 Q2 | 816.51 Million JPY | 6.58% |
| 2011 Q4 | 2.03 Billion JPY | 74.74% |
| 2011 Q1 | 1.17 Billion JPY | -31.61% |
| 2011 FY | - JPY | 7.44% |
| 2011 Q3 | 1.16 Billion JPY | 20.86% |
| 2011 Q2 | 964.13 Million JPY | -18.24% |
| 2010 Q4 | 1.72 Billion JPY | 50.79% |
| 2010 Q2 | 927.35 Million JPY | -21.36% |
| 2010 Q3 | 1.14 Billion JPY | 23.32% |
| 2010 Q1 | 1.17 Billion JPY | -35.82% |
| 2010 FY | - JPY | 21.65% |
| 2009 Q1 | 766.11 Million JPY | 0.0% |
| 2009 Q2 | 631.8 Million JPY | -17.53% |
| 2009 Q3 | 853.9 Million JPY | 35.15% |
| 2009 Q4 | 1.83 Billion JPY | 115.18% |
| 2009 FY | - JPY | 16.31% |
| 2008 FY | - JPY | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Pharma Foods International Co., Ltd. | 6.02 Billion JPY | -14.3% |
| Takeda Pharmaceutical Company Limited | 874.6 Billion JPY | 99.213% |
| Sumitomo Pharma Co., Ltd. | -281.07 Billion JPY | 102.448% |
| Shionogi & Co., Ltd. | 186.7 Billion JPY | 96.314% |
| Wakamoto Pharmaceutical Co.,Ltd. | 570.97 Million JPY | -1105.313% |
| Nippon Shinyaku Co., Ltd. | 36.29 Billion JPY | 81.036% |
| Kaken Pharmaceutical Co., Ltd. | 12.26 Billion JPY | 43.898% |
| Eisai Co., Ltd. | 103.1 Billion JPY | 93.325% |
| Morishita Jintan Co., Ltd. | 1.29 Billion JPY | -432.251% |
| Hisamitsu Pharmaceutical Co., Inc. | 18.34 Billion JPY | 62.475% |
| Mochida Pharmaceutical Co., Ltd. | 8.97 Billion JPY | 23.303% |
| Fuso Pharmaceutical Industries,Ltd. | 3.67 Billion JPY | -87.52% |
| Nippon Chemiphar Co., Ltd. | 1.4 Billion JPY | -390.52% |
| Tsumura & Co. | 30.77 Billion JPY | 77.636% |
| Kissei Pharmaceutical Co., Ltd. | 18.72 Billion JPY | 63.237% |
| Torii Pharmaceutical Co., Ltd. | 5.27 Billion JPY | -30.563% |
| Towa Pharmaceutical Co., Ltd. | 35.53 Billion JPY | 80.634% |
| Zeria Pharmaceutical Co., Ltd. | 17.52 Billion JPY | 60.723% |
| KYORIN Holdings, Inc. | 10.29 Billion JPY | 33.159% |
| Taiko Pharmaceutical Co.,Ltd. | -3.75 Billion JPY | 283.52% |
| Daito Pharmaceutical Co.,Ltd. | 7.55 Billion JPY | 8.884% |
| SymBio Pharmaceuticals Limited | -714 Million JPY | 1063.866% |
| MedRx Co., Ltd | -884.51 Million JPY | 878.053% |
| Mizuho Medy Co.,Ltd. | 5.53 Billion JPY | -24.307% |
| Solasia Pharma K.K. | -635 Million JPY | 1183.78% |
| Modalis Therapeutics Corporation | -2.37 Billion JPY | 389.9% |
| ASKA Pharmaceutical Holdings Co.,Ltd. | 9.16 Billion JPY | 24.894% |
| Sawai Group Holdings Co., Ltd. | 36.87 Billion JPY | 81.336% |
| Cyfuse Biomedical K.K. | -538.28 Million JPY | 1378.495% |
| Toho Holdings Co., Ltd. | 25.84 Billion JPY | 73.372% |
| Koa Shoji Holdings Co.,Ltd. | 5.1 Billion JPY | -34.898% |